Please ensure Javascript is enabled for purposes of website accessibility

Why Sangamo Biosciences, Inc. Trounced the Market

By Dave Williamson – Mar 6, 2014 at 7:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sangamo Biosciences shot up 20% today, but this may still be one to watch at a distance.

Shares of Sangamo Biosciences (SGMO -3.98%) are up more than 20% today on the news that HIV patients who were given Bristol-Myers Squibb's (BMY 1.07%) drug Cytoxan responded better to Sangamo's drug SB-728-T, which is made up of the patient's own genetically modified cells.

However, in this video, Motley Fool health-care analyst David Williamson points to a few things that investors need to keep in mind that should temper some of the enthusiasm. Firstly, the success story here was only two patients, and secondly, with Sangamo's drug, the virus is stabilized, but still detectable. Comparing this against current anti-viral drugs, which bring the virus down to undetectable levels, means Sangamo will still need to do better if it wants patients to switch. David takes a close look at the company in this video, discusses its financial situation, and points to some key trials coming up that will give investors a much better idea whether they should be jumping in on this stock.

David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.